T Schmidt1, M Hoch1, S S Lotfi Jad1, F Solimani1, G Di Zenzo2, A V Marzano3, M Goebeler4, E Cozzani5, J S Kern6, C Sitaru6, I Lakoš Jukić7, M Sárdy8, S Uzun9, H Jedlickova10, R Gläser11, M Kaneda12, R Eming1, G Göpel1, N Ishii13, B Greene14, T Hashimoto13, M Hertl1. 1. Department of Dermatology and Allergology, Philipps-University, Marburg, D-35043, Germany. 2. Istituto Dermopatico dell'Immacolata, Rome, Italy. 3. Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano - Unità Operativa di Dermatologia, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. 4. Department of Dermatology, Venereology and Allergology, Julius-Maximilians-University Würzburg, Würzburg, Germany. 5. Dermatology, IRCCS AOU San Martino Di.S.Sal., Genoa, Italy. 6. Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany. 7. Department of Dermatovenerology, University of Zagreb, Zagreb, Croatia. 8. München, Department of Dermatology and Allergology, Ludwig Maximilians University Munich, Munich, Germany. 9. Department of Dermatology and Venereology, Faculty of Medicine, Akdeniz University, Antalya, Turkey. 10. Department of Dermatovenereology, St. Anna University Hospital, Masaryk University, Brno, Czech Republic. 11. Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany. 12. Medical and Biological Laboratories, Co. Ltd, Nagoya, Japan. 13. Department of Dermatology, Kurume University School of Medicine, Kurume, Japan. 14. Institute of Biometry and Statistics, Philipps-University Marburg, D-35043, Marburg, Germany.
Abstract
BACKGROUND: Epidermolysis bullosa acquisita (EBA) is a rare, potentially devastating autoimmune disease of the skin. IgG autoantibodies directed against type VII collagen (Col7), the major component of anchoring fibrils, induce skin fragility leading to cutaneous and mucocutaneous blister formation, which is mostly of a scarring phenotype. Thus, powerful and reproducible diagnostic assays are critical to establish the diagnosis of EBA early to avoid irreversible sequelae. OBJECTIVES: The present international, retrospective multicentre study included a large cohort of patients with EBA and evaluated the diagnostic power of four different diagnostic assays for the detection of anti-Col7 IgG autoantibodies. METHODS: Overall, 95 EBA sera and 200 control sera consisting of 100 bullous pemphigoid sera, 50 pemphigus vulgaris sera and 50 sera of healthy controls were tested for anti-Col7 IgG autoantibodies using indirect immunofluorescence (IIF), two commercial enzyme-linked immunosorbent assay (ELISA) systems and Western blot (WB) analysis. EBA sera were taken from patients with positive direct immunofluorescence and IgG reactivity in at least one of the immunoserological assays (IIF, ELISA, WB). RESULTS: A Col7-NC1/NC2 ELISA (MBL, Nagoya, Japan) showed the highest sensitivity (97·9%), followed by a Col7-NC1 ELISA (Euroimmun, Lübeck, Germany) (89·5%), WB with Col7-NC1 (85·3%), and IIF on saline-split human skin (74·7%). The specificities of both ELISA systems were comparable (NC1 98·7%, NC1/NC2 99·3%). Furthermore, WB was more sensitive than IIF, which was more specific. CONCLUSIONS: The two commercially available ELISA systems allow for a highly sensitive and specific diagnosis of EBA. The sensitivity of the Col7-NC1/NC2 ELISA is significantly higher compared with the ELISA based on the Col7-NC1 domain only.
BACKGROUND: Epidermolysis bullosa acquisita (EBA) is a rare, potentially devastating autoimmune disease of the skin. IgG autoantibodies directed against type VII collagen (Col7), the major component of anchoring fibrils, induce skin fragility leading to cutaneous and mucocutaneous blister formation, which is mostly of a scarring phenotype. Thus, powerful and reproducible diagnostic assays are critical to establish the diagnosis of EBA early to avoid irreversible sequelae. OBJECTIVES: The present international, retrospective multicentre study included a large cohort of patients with EBA and evaluated the diagnostic power of four different diagnostic assays for the detection of anti-Col7 IgG autoantibodies. METHODS: Overall, 95 EBA sera and 200 control sera consisting of 100 bullous pemphigoid sera, 50 pemphigus vulgaris sera and 50 sera of healthy controls were tested for anti-Col7 IgG autoantibodies using indirect immunofluorescence (IIF), two commercial enzyme-linked immunosorbent assay (ELISA) systems and Western blot (WB) analysis. EBA sera were taken from patients with positive direct immunofluorescence and IgG reactivity in at least one of the immunoserological assays (IIF, ELISA, WB). RESULTS: A Col7-NC1/NC2 ELISA (MBL, Nagoya, Japan) showed the highest sensitivity (97·9%), followed by a Col7-NC1 ELISA (Euroimmun, Lübeck, Germany) (89·5%), WB with Col7-NC1 (85·3%), and IIF on saline-split human skin (74·7%). The specificities of both ELISA systems were comparable (NC1 98·7%, NC1/NC2 99·3%). Furthermore, WB was more sensitive than IIF, which was more specific. CONCLUSIONS: The two commercially available ELISA systems allow for a highly sensitive and specific diagnosis of EBA. The sensitivity of the Col7-NC1/NC2 ELISA is significantly higher compared with the ELISA based on the Col7-NC1 domain only.
Authors: René Reitermaier; Michael Skoll; Veronique Touzeau-Roemer; Maximilian C Aichelburg; Adelheid Elbe-Bürger; Wolfgang Bauer; Armin Rieger; Christopher Schuster Journal: Acta Derm Venereol Date: 2021-11-24 Impact factor: 3.875
Authors: Sandra Saschenbrecker; Ingolf Karl; Lars Komorowski; Christian Probst; Cornelia Dähnrich; Kai Fechner; Winfried Stöcker; Wolfgang Schlumberger Journal: Front Immunol Date: 2019-08-20 Impact factor: 7.561
Authors: E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux Journal: J Eur Acad Dermatol Venereol Date: 2021-07-26 Impact factor: 6.166